公开(公告)号：US20220005197A1

公开(公告)日：2022-01-06

申请号：US17280123

申请日：2019-09-25

申请人： UNIVERSITÉ CLAUDE BERNARD LYON 1 ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,  ASSOCIATION FRANÇAISE CONTRE LES MYOPATHIES

发明人： Tessa Homan ,  Hélène Delanoe-Ayari ,  Adrien Moreau ,  Alexandre Mejat

IPC分类号： G06T7/00 ,  G06T7/246

摘要： A method for analysis of cellular contractions of cells comprises recording a sequence of images of the cells. The sequence comprises a first image and a second image. The position of points of note in the first image are determined. The position of the same points of note in the second image, and for at least one point of note of the first image, is determined. A correspondence is established between the point of note of the first image and a point of note of the second image. The movement of the point of note, between the first image and the second image, is determined by comparing the position of the point of note of the first image and the position of the corresponding point of note of the second image.

公开(公告)号：US20210393760A1

公开(公告)日：2021-12-23

申请号：US17151516

申请日：2021-01-18

申请人： INSTITUT PASTEUR ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

发明人： Salah MECHERI ,  Robert MENARD ,  Claudia DEMARTA-GATSI

IPC分类号： A61K39/015 ,  A61P33/06 ,  A61K35/68 ,  C07K16/20 ,  G01N33/569

摘要： A method of generating an antibody and cellular immune response against a Plasmodium in a primate, comprising administering at least 103 genetically modified live Plasmodium to the primate, wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein, to thereby induce an antibody and cellular immune response against the Plasmodium in the primate. In some embodiments at least 104 genetically modified live Plasmodium is administered to the primate. An immunogenic composition for administration to a primate, comprising a at least 103 genetically modified live Plasmodium wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein; and at least one pharmaceutically acceptable excipient and/or support. In some embodiments the immunogenic composition comprises at least 103 genetically a modified live Plasmodium.

公开(公告)号：US11203753B2

公开(公告)日：2021-12-21

申请号：US15557646

申请日：2016-03-14

申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS ,  UNIVERSITE PARIS DESCARTES ,  UNIVERSITE PARIS DIDEROT—PARIS 7

发明人： Carole Peyssonnaux ,  Jacques Mathieu ,  Sara Zumerle

IPC分类号： C07K16/26 ,  A61K9/00 ,  C12N15/113 ,  A61K31/713 ,  A61K31/7105 ,  A61K31/77 ,  C12N15/115

摘要： The present invention relates to a hepcidin antagonist for use in the treatment of inflammatory diseases.

公开(公告)号：US11154598B2

公开(公告)日：2021-10-26

申请号：US16089754

申请日：2017-03-29

申请人： UNIVERSITÉ DE PARIS ,  Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Assistance Publique—Hopitaux de Paris

发明人： Sébastien Jauliac ,  Livia Camargo

IPC分类号： A61K35/12 ,  A61K9/00 ,  A61K39/00 ,  A61K39/39 ,  A61P35/04 ,  A61K35/13 ,  C07K14/47 ,  C12Q1/6886

摘要： The present invention relates to a composition comprising secreted extracellular vesicles (SEV) of cells expressing nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4(NFATC4), for use in the treatment of cancer or in the treatment or prevention of metastatic cancer. It further relates to in vitromethods for determining or predicting the therapeutic efficiency of a treatment with a composition comprising SEV of cells expressing NFATC4 in a cancer patient, based on the ability of the composition comprising SEV of cells expressing NFATC4 to induce an increase in TGFβ1 expression level.

公开(公告)号：US11130950B2

公开(公告)日：2021-09-28

申请号：US15739366

申请日：2016-07-01

申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)

发明人： Olivier Tabary ,  Florence Sonneville

IPC分类号： C12N15/113 ,  A61P11/00

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of cystic fibrosis. In particular, the present invention relates to a method of treating cystic fibrosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a nucleic acid miR-9 inhibitor.

公开(公告)号：US20210292408A1

公开(公告)日：2021-09-23

申请号：US16319956

申请日：2017-07-28

申请人： INSERM (Institut National de la Sante et de la Recherche Medicale) ,  Universite Paul Sabatier Toulouse III ,  Centre National de la Recherche Scientifique (CNRS) ,  Centre Hospitalier Universitaire de Toulouse ,  Institut Claudius Regaud

发明人： Mary POUPOT ,  Loïc YSEBAERT ,  Marie TOSOLINI ,  Jean-Jacques FOURNIE ,  Pierre BROUSSET ,  Philippe ROCHAIX

IPC分类号： C07K16/28 ,  G01N33/574

摘要： The present invention relates to antibodies targeting Tumor Associated Macrophages (TAMs) and uses thereof. The inventors investigated specific marker exposed on the surface of the macrophages associated to tumor in order to detect and target TAMs. They showed that sideroflexin 3, which is absent in normal macrophage, is expressed by tumor associated macrophages. The inventors further demonstrated that using antibody directed to sideroflexin 3, they depleted TAMs in PBMC sample obtained from LCC patient, and strongly reduced leukemic B cells number.

公开(公告)号：US20210283271A1

公开(公告)日：2021-09-16

申请号：US17330902

申请日：2021-05-26

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITE DE NANTES ,  CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES

发明人： Mathieu MEVEL ,  David DENIAUD ,  Eduard AYUSO

IPC分类号： A61K47/69 ,  A61K48/00 ,  A61K49/18 ,  C12N7/00

摘要： The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety.
Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats. The present invention further relates to a method for chemically coupling an Adeno-Associated Virus (AAV) vector particle with at least one ligand L and to a Recombinant Adeno-Associated Virus (rAAV) vector particle obtained by said method as well as a pharmaceutical composition comprising it and their corresponding medical use.

公开(公告)号：US20210282862A1

公开(公告)日：2021-09-16

申请号：US17334566

申请日：2021-05-28

申请人： SpineGuard ,  Sorbonne Universite ,  INSERM (Institut National de la Sante et de la Recherche Medicale) ,  Centre National de la Recherche Scientifique - CNRS

发明人： Maurice BOURLION ,  Olivier FREZAL ,  Guillaume MOREL ,  Stephane BETTE ,  Thibault CHANDANSON ,  Florian RICHER ,  Valentin KERSPERN

IPC分类号： A61B34/10 ,  A61B34/20 ,  A61B34/30 ,  A61B17/16

摘要： Systems, instruments, and methods are provided verifying that a robotic surgery is being performed in accordance with a surgical plan, wherein a surgical tool having a sensor outputs a data signal that enables the trajectory of the surgical tool to be displayed as an overlay on an image of an anatomical portion of a patient and a visual or audible signal that confirms the surgical tool is penetrating the anatomical portion in accordance with the surgical plan and/or that issues an alert indicating that the surgical tool is not being inserted into the anatomical portion according to the surgical plan.

公开(公告)号：US11116763B2

公开(公告)日：2021-09-14

申请号：US16317091

申请日：2017-07-13

申请人： UNIVERSITÉ DE PARIS ,  Assistance Publique—Hopitaux de Paris ,  Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Centre National de la Recherche Scientifique (CNRS) ,  Sorbonne Universite

发明人： Nicolas Dupin ,  Vincent Calvez ,  Philippe Grange ,  Anne-Geneviève Marcelin

IPC分类号： A61K31/53 ,  A61P17/10 ,  A61P17/06 ,  A61K31/495 ,  A61K45/06 ,  A61K31/202 ,  A61K31/203

摘要： The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.

公开(公告)号：US20210270816A1

公开(公告)日：2021-09-02

申请号：US17257405

申请日：2019-07-10

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  ASSISTANCE PUBLIQUE - HOPITAUX DE MARSEILLE ,  AIX-MARSEILLE UNIVERSITE

发明人： Annie VIALLAT ,  Emmanuele HELFER ,  Catherine BADENS ,  Scott ATWELL ,  Anne CHARRIER

IPC分类号： G01N33/50

摘要： The invention is related to a method for measuring the variability of the red blood cells deformability of an individual by determining the amount of red blood cells having a tank-treading motion in a population of red blood cells from a tested blood sample of said individual, and comparing the amount to a reference amount. The determination of the amount of red blood cells having a tank-treading motion is carried out using a visualisation means such as a brightfield microscope.